-
The Veterinary Clinics of North... Sep 2019
Topics: Animals; Neoplasms
PubMed: 31345517
DOI: 10.1016/j.cvsm.2019.06.001 -
Herz Mar 2024Cardiovascular diseases and cancer have a complex relationship and show a reciprocal linkage and influence. Mutual risk factors, demographic changes and increasing... (Review)
Review
Cardiovascular diseases and cancer have a complex relationship and show a reciprocal linkage and influence. Mutual risk factors, demographic changes and increasing multimorbidity result in an increase in the incidence of both diseases. Advances in oncological and cardiological treatment lead to a further increase in patients with cured or chronic diseases as a relevant comorbidity. The induction of cardiovascular side effects by cancer therapies leads to increased cardiovascular morbidity and mortality in cancer patients. Recent data also show that cardiovascular disease, through various factors, can also promote the development and progression of cancer. An understanding of the interrelationship between cardiovascular diseases and cancer can be seen as a major medical challenge for the future. To this end, scientific, structural, clinical and educational interfaces between cardiology and oncology are essential. This article outlines the complex relationships between cardiovascular diseases and cancer and defines current and future challenges for the best possible care of affected patients.
Topics: Humans; Cardiovascular Diseases; Cardio-Oncology; Cardiotoxicity; Neoplasms; Medical Oncology
PubMed: 38289420
DOI: 10.1007/s00059-024-05232-7 -
International Journal of Radiation... 2022Laboratory and clinical research are essential for advancing radiation research; however, there is a growing awareness that conventional laboratory animal models and... (Review)
Review
PURPOSE
Laboratory and clinical research are essential for advancing radiation research; however, there is a growing awareness that conventional laboratory animal models and early-phase clinical studies in patients have not improved the low success rates and late-stage failures in new cancer therapy efforts. There are considerable costs and inefficiencies in moving preclinical research into effective cancer therapies for patients. Canine translational models of radiation research can fill an important niche between rodent and human studies, ultimately providing valuable, predictive, translational biological and clinical results for human cancer patients. Companion dogs naturally and spontaneously develop cancers over the course of their lifetime. Many canine tumor types share important similarities to human disease, molecularly and biologically, with a comparable clinical course. Dogs receive state-of-the-art medical care, which can include radiotherapy, experimental therapeutics, and novel technologies, offering an important opportunity for radiobiology and radiation oncology research. Notably, the National Cancer Institute has developed the Comparative Oncology Program to promote this area of increased research interest.
CONCLUSION
In this review, the benefits and limitations of performing translational radiation research in companion dogs will be presented, and current research utilizing the canine model will be highlighted, including studies across research areas focusing on common canine tumor types treated with radiotherapy, comparative normal tissue effects, radiation and immunology research, and alternative radiation therapy approaches involving canine cancer patients.
Topics: Animals; Dogs; Humans; Models, Animal; Neoplasms; Radiobiology; Translational Research, Biomedical
PubMed: 34586958
DOI: 10.1080/09553002.2021.1987572 -
Bulletin Du Cancer Jan 2022Once again this year, the Editorial Board presents here a summary of the most important advances in treatment and patient care in oncology over the past year. Some of... (Review)
Review
Once again this year, the Editorial Board presents here a summary of the most important advances in treatment and patient care in oncology over the past year. Some of the most important results in breast and gynecological cancers (endometrium and cervix), lung, brain, urologic and digestive cancers. Are also presented progresses in hematological malignancies, pediatric oncology, and of course supportive care essential for our patients.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Gastrointestinal Neoplasms; Hematologic Neoplasms; Humans; Immunotherapy; Lung Neoplasms; Male; Medical Oncology; Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Urologic Neoplasms; Uterine Cervical Neoplasms
PubMed: 34980367
DOI: 10.1016/j.bulcan.2021.12.003 -
European Journal of Nuclear Medicine... Jul 2023
Topics: Humans; Poland; Medical Oncology; Diagnostic Imaging; Neoplasms
PubMed: 37037930
DOI: 10.1007/s00259-023-06216-1 -
Pathologie (Heidelberg, Germany) May 2024Due to the considerable technological progress in molecular and genetic diagnostics as well as increasing insights into the molecular pathogenesis of diseases, there has... (Review)
Review
Due to the considerable technological progress in molecular and genetic diagnostics as well as increasing insights into the molecular pathogenesis of diseases, there has been a fundamental paradigm shift in the past two decades from a "one-size-fits-all approach" to personalized, molecularly informed treatment strategies. Personalized medicine or precision medicine focuses on the genetic, physiological, molecular, and biochemical differences between individuals and considers their effects on the development, prevention, and treatment of diseases. As a pioneer of personalized medicine, the field of oncology is particularly noteworthy, where personalized diagnostics and treatment have led to lasting change in the treatment of cancer patients in recent years. In this article, the significant change towards personalized treatment concepts, especially in the field of personalized oncology, will be discussed and examined in more detail.
Topics: Precision Medicine; Humans; Neoplasms; Medical Oncology
PubMed: 38568256
DOI: 10.1007/s00292-024-01315-8 -
JAAPA : Official Journal of the... Apr 2023Each cancer has a unique fingerprint, and precision oncology can be used to more effectively fight malignancies. The identified genes, expressed RNA, and proteins...
Each cancer has a unique fingerprint, and precision oncology can be used to more effectively fight malignancies. The identified genes, expressed RNA, and proteins expressed in patients' cancers are now used routinely to predict prognosis and inform treatment recommendations. This article describes how malignancies develop and some of the targeted drugs that can be used against them.
Topics: Humans; Neoplasms; Precision Medicine; Molecular Targeted Therapy; Medical Oncology; Prognosis
PubMed: 36976031
DOI: 10.1097/01.JAA.0000911196.91455.72 -
British Journal of Cancer Oct 2022Biomarker-guided treatment selection has transformed cancer management. Pruis et al. provide a powerful example of the challenges and promises of whole genome sequencing...
Biomarker-guided treatment selection has transformed cancer management. Pruis et al. provide a powerful example of the challenges and promises of whole genome sequencing to match patients with advanced cancer for precision oncology studies and targeted therapies. Expanding genomic testing platforms are reviewed with a view towards future applications to inform clinical cancer research and practice.
Topics: Biomarkers, Tumor; Humans; Medical Oncology; Neoplasms; Precision Medicine
PubMed: 36064588
DOI: 10.1038/s41416-022-01967-4 -
Current Oncology (Toronto, Ont.) Oct 2019The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference was held in Halifax, Nova Scotia, 20-22 September 2018. Experts in radiation oncology, medical...
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference was held in Halifax, Nova Scotia, 20-22 September 2018. Experts in radiation oncology, medical oncology, surgical oncology, and pathology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of pancreatic cancer, pancreatic neuroendocrine tumours, hepatocellular cancer, and rectal and colon cancer, including ■ surgical management of pancreatic adenocarcinoma,■ adjuvant and metastatic systemic therapy options in pancreatic adenocarcinoma,■ the role of radiotherapy in the management of pancreatic adenocarcinoma,■ systemic therapy in pancreatic neuroendocrine tumours,■ updates in systemic therapy for patients with advanced hepatocellular carcinoma,■ optimum duration of adjuvant systemic therapy for colorectal cancer, and■ sequence of therapy in oligometastatic colorectal cancer.
Topics: Canada; Consensus; Gastrointestinal Neoplasms; Humans; Medical Oncology
PubMed: 31708660
DOI: 10.3747/co.26.5193 -
American Society of Clinical Oncology... Apr 2022New approaches to cancer survivorship care must address the rising number of survivors who need complex care; the need to personalize care to improve health equity;... (Review)
Review
New approaches to cancer survivorship care must address the rising number of survivors who need complex care; the need to personalize care to improve health equity; workforce shortages and clinician knowledge deficits about the long-term and late effects of cancer; the need to engage and coordinate oncology, primary care, and a large multidisciplinary team of subspecialists and programs to meet survivors' needs; and the need to control costs and deliver better value. This review proposes eight core tenets of an evolved standard of care to meet these needs by starting at diagnosis and continuing throughout oncology and into follow-up to: (1) facilitate team medicine by connecting oncology, primary care, subspecialists and programs, researchers, and patients and caregivers; (2) educate patients and support them in self-management; (3) mitigate toxicities; (4) manage comorbidities; (5) promote healthy behaviors and wellness; (6) improve health equity; (7) provide clear personalized follow-up; and (8) provide ongoing opportunities for participation in research as the standard of care. Strategies to successfully implement this care are discussed from the perspectives of oncology, primary care, and health care administration.
Topics: Cancer Survivors; Humans; Medical Oncology; Neoplasms; Patient Care; Survivors; Survivorship
PubMed: 35649204
DOI: 10.1200/EDBK_349391